A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

Guy Pratt, Christina Yap, Ceri Oldreive, Daniel Slade, Rebecca Bishop, Mike Griffiths, Martin J S Dyer, Chris Fegan, David Oscier, Andrew Pettitt, Estella Matutes, Stephen Devereux, David Allsup, Adrian Bloor, Peter Hillmen, George Follows, Simon Rule, Paul Moss, Tatjana Stankovic

Research output: Contribution to journalLetterpeer-review

7 Citations (Scopus)
333 Downloads (Pure)
Original languageEnglish
Pages (from-to)429-433
JournalBritish Journal of Haematology
Issue number3
Early online date23 Jun 2017
Publication statusPublished - Aug 2018


  • Letter
  • chronic lymphocytic leukaemia
  • mantle cell lymphoma
  • DNA damage
  • olaparib

Cite this